Report Overview

The European Alzheimers Therapeutics and diagnostics market is expected to reach a CAGR of approximately 5.42% during the forecast period.

Alzheimers is a neurodegenerative disease that usually starts slowly and then progressively worsens. Alzheimers disease is the only incurable disease on the top 5 leading causes of death worldwide. Worldwide, there are approximately 46.8 million people living with Alzheimers or other forms of dementia. Sweden is the fifth most affected country by Alzheimers. Alzheimers is a disease of dementia that primarily affects the people. It gradually breaks down brain tissue and impairs memory and other aspects of intellect. This has a major impact on the quality of life of people which makes the market environment extremely favourable for new product launches targeting either diagnostics or therapeutics.



Market Drivers

Alzheimers Diagnostics and Therapeutics in Sweden is mainly driven by the increase in prevalence of Dementia related illnesses. This is compounded by the rise in geriatric population owing to increasing survival rates because of improved health and living conditions among the people of the country.

The increasing efforts of the government coupled with apt co-ordination between the medical care services and social services propel the market growth. The rise in per capita spending on healthcare services by the people of Sweden also drives the market.

The market is driven by new drugs and diagnostic technologies in the pipeline.